Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI

Bioxcel Therapeutics (BTAI) Financial Statements

1,277 Followers

Bioxcel Therapeutics Financial Overview

Bioxcel Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.182; its P/E ratio is -0.23; Bioxcel Therapeutics is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is $-0.71. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 582.00K$ 376.00K$ 341.00K$ 457.00K$ 206.00K
Gross Profit$ 502.00K$ -337.00K$ -171.00K$ 431.00K$ 197.00K
EBIT$ -23.18M$ -18.82M$ -47.23M$ -50.26M$ -49.43M
EBITDA$ -22.99M$ -18.15M$ -46.78M$ -49.82M$ -49.02M
Net Income Common Stockholders$ -26.79M$ -22.26M$ -50.49M$ -53.52M$ -52.80M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 74.14M$ 65.22M$ 89.96M$ 127.55M$ 165.52M
Total Assets$ 82.32M$ 73.70M$ 100.45M$ 140.10M$ 179.10M
Total Debt$ 101.98M$ 101.04M$ 99.62M$ 97.46M$ 95.77M
Net Debt$ 27.84M$ 35.82M$ 9.66M$ -30.08M$ -69.76M
Total Liabilities$ 154.69M$ 130.21M$ 141.06M$ 134.23M$ 127.10M
Stockholders Equity$ -72.36M$ -56.51M$ -40.61M$ 5.86M$ 53.01M
Cash Flow-
Free Cash Flow$ -17.71M$ -26.86M$ -37.58M$ -38.23M$ -52.35M
Operating Cash Flow$ -17.71M$ -26.86M$ -37.58M$ -38.21M$ -52.35M
Investing Cash Flow---$ -20.00K-
Financing Cash Flow$ 26.63M$ 2.12M-$ 250.00K$ 24.15M
Currency in USD

Bioxcel Therapeutics Earnings and Revenue History

Bioxcel Therapeutics Debt to Assets

Bioxcel Therapeutics Cash Flow

Bioxcel Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis